Cargando…
Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment
INTRODUCTION: Bortezomib (BTZ) is a selective and reversible proteasome inhibitor and first line treatment for multiple myeloma (MM). One of the side effects is BTZ-induced peripheral neuropathy (BIPN). Until now there is no biomarker which can predict this side effect and its severity. Neurofilamen...
Autores principales: | Cebulla, Nadine, Schirmer, Daniel, Runau, Eva, Flamm, Leon, Gommersbach, Sonja, Stengel, Helena, Zhou, Xiang, Einsele, Hermann, Reinhold, Ann-Kristin, Rogalla von Bieberstein, Bruno, Zeller, Daniel, Rittner, Heike, Kortüm, K. Martin, Sommer, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188420/ https://www.ncbi.nlm.nih.gov/pubmed/36802032 http://dx.doi.org/10.1007/s00415-023-11624-2 |
Ejemplares similares
-
Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
por: Zhou, Xiang, et al.
Publicado: (2023) -
Systemic inflammatory markers in patients with polyneuropathies
por: García-Fernández, Patricia, et al.
Publicado: (2023) -
Neurofilament-dependent Radial Growth of Motor Axons and Axonal Organization of Neurofilaments Does Not Require the Neurofilament Heavy Subunit (NF-H) or Its Phosphorylation
por: Rao, Mala V., et al.
Publicado: (1998) -
The Mobility of Neurofilaments in Mature Myelinated Axons of Adult Mice
por: Fenn, J. Daniel, et al.
Publicado: (2023) -
Control of axonal caliber by neurofilament transport
Publicado: (1984)